Abstract
Lipokon™ is an innovative technology platform delivers the enhancement of oral bioavailability, stability and protection across nutraceuticals with differing solubility and physicochemical profiles through molecular-level encapsulation and amorphization. This research applies the Lipokon™ platform for four nutraceutically diverse actives: berberine, caffeine, curcumin, and resveratrol, and comprehensively evaluates the resulting formulations with respect to solid-state behavior, colloidal properties, and in vitro performance. All formulations exhibited homogeneous appearance, physiologically compatible pH, and controlled moisture content, ensuring physical and chemical stability. Powder X-ray diffraction (XRD) and Differential Scanning Calorimetry (DSC) revealed a dramatic transition from crystalline raw materials to predominantly amorphous states. Particle size analysis revealed nanometric lipid assemblies with Zaverage values ranging up to 200 nm.
All formulations demonstrated high structural uniformity (Polydispersity Index (PdI): NMT 0.5) and maintained stable negative zeta potentials with lower negative values, ensuring colloidal integrity through effective electrostatic and steric stabilization. Field emission scanning electron microscopy (SEM) and transmission electron microscopy (TEM) showed morphological transformation from angular crystalline particles to uniform nanostructured spherical particles. Energydispersive X-ray spectroscopy confirmed molecular-level encapsulation through elevated oxygen content and persistent phospholipid signatures, indicating successful lipid matrix integration. Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopy validated amorphization while confirming chemical integrity without degradation. In vitro dissolution studies demonstrated superior and nearly complete release performance for Lipokon™ Caffeine, which achieved in immediately, while Lipokon™ Resveratrol exhibited controlled biphasic release. These comprehensive findings establish Lipokon™ as a robust, scalable delivery platform capable of transforming crystalline actives into bioavailable formulations while maintaining adaptability across chemically diverse molecules, offering significant potential for enhanced therapeutic efficacy and clinical application.
Introduction
Liposomes are phospholipid bilayers that are self-assembled and most broadly used and applicable nanocarrier systems to deliver bioactive compounds in the pharmaceutical, nutraceutical, cosmetic, and functional foods industry (1). Their amphiphilic nature allows small-sized structures to encapsulate hydrophilic molecules internally and lipophilic molecules externally, offering greater solubility, chemical and enzymatic stability, with protection against environmental degradation, and controlled release characteristics of a wide variety of actives (2, 3). Despite these intrinsic benefits, traditional liposomes exhibit several limitations that hinder their translational and commercial applicability. Notably, they demonstrate lower target specificity, resulting in insufficient accumulation at the intended site of action and unintended distribution to non-target tissues (4). The mononuclear phagocytic system rapidly recognizes and clears circulating particles, thereby reducing the systemic circulation time and early leakage of encapsulated products (5,6). Consequently, conventional liposomes exhibit a short half-life and poor retention of encapsulated components (7). Despite advances in liposomal formulation science, maintaining high loading efficiency across structurally diverse molecules remains challenging (8). Small molecules with hydrophilic properties are likely to have poor encapsulation efficiency because they easily diffuse between the lipid bilayer or are weakly held by the hydrophilic aqueous core. On the other hand, with increasing concentration, highly lipophilic molecules can interfere with bilayer packing and vesicle integrity of the bilayers, which frequently causes rapid leakage or burst release (9,10). Traditional passive loading techniques, such as thin-film hydration, ethanol injection, and reverse-phase evaporation, are widely employed; however, they typically require a high lipid-to-drug ratio and suffer from limitations including poor drug retention, non-uniform structural stability, and limited reproducibility (11). Active or remote loading methods, including pH-gradient–mediated mechanisms, have improved the encapsulation of ionizable amphiphilic molecules; however, they are constrained by stringent physicochemical requirements, sensitivity to processing parameters, and applicability to a limited range of compound classes (12). These constraints are more imperative when it comes to commercial scale-up, where consistency in the manufacturing process, cost-effectiveness, and compliance with regulations are imperative.
Additionally, liposomal loading and stability are especially problematic in the nutraceutical industry, where active ingredients vary widely in terms of solubility and permeability properties (13). The Biopharmaceutics Classification System (BCS) can be used to explain these complexities in the above mentioned properties. The greatest formulation challenge, and consequently the highest potential benefit from liposomal encapsulation, is associated with molecules exhibiting both low aqueous solubility and low membrane permeability (BCS Class IV), where delivery systems must simultaneously address solubilization, physicochemical stability, membrane interaction, and controlled release. Compounds characterized by low solubility but adequate permeability (BCS Class II) also strongly benefit from lipidassisted solubilization strategies, which improve dissolution and bioavailability. In contrast, hydrophilic and poorly permeable molecules (BCS Class III) primarily require structural shielding and membraneinteractive carriers to enhance transport across biological barriers (14). Even highly soluble and highly permeable active compounds (BCS Class I) may warrant encapsulation when tissue protection, prolonged residence time, or controlled release is desired (15). As modern nutraceutical formulations increasingly incorporate multiple BCS classes within a single product, the need for sophisticated delivery systems capable of overcoming physicochemical barriers while maintaining industrial manufacturability has become increasingly critical.
Hence, there has been a persistent need to advance lipid composition engineering, optimize vesicle size distribution, implement appropriate surface modifications, and fine-tune processing parameters to prevent vesicle fusion, aggregation, and drug leakage (16). A major unresolved and open-ended challenge remains the translation of laboratory-scale innovations into commercially viable, cost-effective, and reproducible manufacturing systems suitable for real-world nutraceutical products.
To address these unmet needs, the present research proposes ‘LipokonTM’, a state-of-the-art and commercially viable liposomal platform (Konark Herbal and Healthcare Pvt. Ltd) designed to enable highperformance, consistent, and effective encapsulation of nutraceutical actives across all four BCS classes (17). Four model compounds were chosen to reflect varied solubility and permeability values: Caffeine (BCS Class I), Resveratrol (BCS Class II), Berberine hydrochloride (BCS Class III), and Curcumin (BCS Class IV) (18–21). Hence, the use of these molecules in combination represents the full spectrum of challenges encountered in the modern development of nutraceutical products.
This research presents the formulation, optimization, and characterization of Lipokon™ formulations for each model compound, along with a systematic evaluation of encapsulation efficiency, vesicle morphology, particle size distribution, bilayer integrity, release kinetics, and physicochemical stability. This work is expected to enhance scientific understanding as well as the commercial translation of liposomal technologies by establishing a unified, industrially scalable liposomal delivery platform capable of delivering structurally diverse nutraceuticals. These results will support next-generation nutraceutical, functional food, and wellness products requiring high stability, efficacy, and consumer-ready performance in line with current therapeutic and nutritional needs.
Materials
Curcumin (≥95% purity) and Berberine (≥95% purity) were utilized from Konark Herbal and Healthcare Pvt. Ltd., while Resveratrol (≥95% purity) were procured from SMR Biotech and Caffeine (≥95% purity) from Ahimsa natural. Sunflower Lecithin (AmiLife® Standard Sunflower Lecithin) and Soya Phosphatidyl Choline (AmiLife® Soya Phosphatidyl Choline) were purchased from Amitex Agro Product Pvt. Ltd. The modified starch–based encapsulating agents were procured from Ingredion. All materials utilized in the study were of pharmaceutical grade.
See the PDF here
(click the picture to download the paper)
Source: Dr. Praful Patil, Dr. Saraswati Gupta, Ajay Pathak, Madhuri Kshirsagar, Prof. Purnima Amin and Vedant Gupta, Lipokon™ Technology: An Industrially Scalable Approach to High-Performance Nutraceutical anad Herbal Delivery, INTERNATIONAL JOURNAL OF VERSATILE RESEARCH AND ANALYSIS (IJVRA), © 2026 IJVRA, Volume 4, Issue 1, January 2026, ISSN: 2984-8903, IJVRA.ORG
Read more interesting articles on curcumin here:
